Tek antagonists
First Claim
Patent Images
1. A polypeptide comprising a fragment of Tek extracellular domain, wherein the fragment lacks all or part of the region containing fibronectin type III (FNIII) motifs and wherein the polypeptide retains the ability to bind at least one Tek ligand.
0 Assignments
0 Petitions
Accused Products
Abstract
The present invention provides Tek antagonists and methods of inhibiting angiogenesis in a mammal by administering Tek antagonists. The methods are particularly useful in treating diseases or conditions mediated by angiogenesis, such as solid tumors and diseases or conditions characterized by ocular neovascularization.
-
Citations
43 Claims
- 1. A polypeptide comprising a fragment of Tek extracellular domain, wherein the fragment lacks all or part of the region containing fibronectin type III (FNIII) motifs and wherein the polypeptide retains the ability to bind at least one Tek ligand.
- 24. A method of inhibiting angiogenesis in a mammal in need of such treatment, comprising administering to the mammal an inhibition-effective amount of a soluble Tek multimer.
-
32. A method of inhibiting angiogenesis in a mammal in need of such treatment, comprising administering to the mammal an inhibition-effective amount of a compound selected from the group consisting of:
-
(a) a polypeptide comprising a fragment of Tek extracellular domain, wherein the fragment lacks all or part of the region containing fibronectin type III (FNIII) motifs and wherein the polypeptide retains the ability to bind at least one Tek ligand;
(b) a soluble Tek multimer; and
(c) an antibody or antibody fragment that is capable of competitively inhibiting the binding of a Tek ligand to the polypeptide of (a);
wherein the polypeptide, soluble Tek multimer, antibody, or antibody fragment is administered in a composition comprising a pharmaceutically acceptable carrier. - View Dependent Claims (33, 34, 35, 36, 37, 38, 39, 40)
-
-
41. A method of inhibiting the binding of a Tek ligand to Tek in a mammal in need of such treatment, comprising administering to the mammal an inhibition-effective amount of compound selected from the group consisting of:
-
(a) a polypeptide comprising a fragment of Tek extracellular domain, wherein the fragment lacks all or part of the region containing fibronectin type III (FNIII) motifs and wherein the polypeptide retains the ability to bind at least one Tek ligand;
(b) a soluble Tek multimer; and
(c) an antibody or antibody fragment that is capable of competitively inhibiting the binding of a Tek ligand to the polypeptide of (a).
-
Specification